Look For Institutional Buying In Alzamend Neuro Inc (NASDAQ: ALZN)

Alzamend Neuro Inc (ALZN) concluded trading on Wednesday at a closing price of $1.01, with 14.33 million shares of worth about $14.47 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -50.49% during that period and on February 19, 2025 the price saw a loss of about -6.48%. Currently the company’s common shares owned by public are about 5.23M shares, out of which, 5.23M shares are available for trading.

Stock saw a price change of -7.34% in past 5 days and over the past one month there was a price change of -12.93%. Year-to-date (YTD), ALZN shares are showing a performance of -12.93% which decreased to -88.56% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.05 but also hit the highest price of $15.06 during that period. The average intraday trading volume for Alzamend Neuro Inc shares is 124.83K. The stock is currently trading -10.50% below its 20-day simple moving average (SMA20), while that difference is down -13.45% for SMA50 and it goes to -62.09% lower than SMA200.

Alzamend Neuro Inc (NASDAQ: ALZN) currently have 5.23M outstanding shares and institutions hold larger chunk of about 2.09% of that.

The stock has a current market capitalization of $5.49M and its 3Y-monthly beta is at -0.04. It has posted earnings per share of -$6.65 in the same period. It has Quick Ratio of 3.80 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALZN, volatility over the week remained 8.42% while standing at 5.51% over the month.

Stock’s fiscal year EPS is expected to rise by 88.57% while it is estimated to decrease by -1.79% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Ascendiant Capital Markets on October 01, 2021 offering a Buy rating for the stock and assigned a target price of $8 to it.

Most Popular

Related Posts